2.50
Hdl Handle:
http://hdl.handle.net/10547/224557
Title:
Anti-tumor immunity in a model of acute myeloid leukemia
Authors:
Cheuk, Adam T.C.; Wells, James W.; Chan, Lucas; Westwood, Nigel B.; Berger, Stuart A.; Yagita, Hideo; Okumura, Ko; Farzaneh, Farzin; Mufti, Ghulam J.; Guinn, Barbara-Ann
Abstract:
Whole-cell vaccines allow the induction of anti-tumor immune responses without the need to define tumor antigens. We wished to directly compare, for the first time, the capacity of B7-1, B7-2 and 4-1BB ligand (4-1BBL) costimulatory molecules to convert murine and human acute myeloid leukemia (AML) cells into whole vaccines. 32Dc-kit is a murine myeloid cell line, which develops an AML-like disease over a protracted period, emulating human AML disease development. 32Dc-kit cells were modified to express elevated levels of B7-1, B7-2 or 4-1BBL, and each led to tumor rejection, although only mice injected with 32Dc-kit/B7-2 cells were able to reject subsequent parental tumor cell challenge. T-cell deficient nude mice were able to reject the 32Dc-kit variants, but they could not reject parental cell challenge; however, we found no evidence of cytotoxic T lymphocyte or natural killer (NK) activity ex vivo suggesting that tumor cell killing was mediated by an immune response that could not be recapitulated using purified NK or T cells as lone effectors. In human allogeneic mixed lymphocyte reactions (MLRs), we found no single costimulatory molecule was more effective, suggesting that the induction of a universal anti-tumor response will require a combination of costimulatory molecules.
Affiliation:
Department of Haematological Medicine, Allergy & Respiratory Science, MRC/Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London School of Medicine, London, UK.
Citation:
Cheuk, A.T.C., Wells, J.W., Chan, L., Westwood, N.B., Berger, S.A., Yagita, H., Okumura, K., Farzaneh, F., Mufti, G.J., Guinn, B.A. (2009) 'Anti-tumor immunity in a model of acute myeloid leukemia', Leukemia and Lymphoma, 50 (3) , pp.447-54.
Publisher:
informa healthcare
Journal:
Leukemia & lymphoma
Issue Date:
Mar-2009
URI:
http://hdl.handle.net/10547/224557
DOI:
10.1080/10428190802653776
PubMed ID:
19197726; 19197726
Additional Links:
http://www.tandfonline.com/doi/abs/10.1080/10428190802653776?journalCode=ilal20
Type:
Article
Language:
en
ISSN:
1029-2403
Sponsors:
Leukaemia and Lymphoma Research, Cancer Research U.K.
Appears in Collections:
Biomedicine and Nutrition Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorCheuk, Adam T.C.en_GB
dc.contributor.authorWells, James W.en_GB
dc.contributor.authorChan, Lucasen_GB
dc.contributor.authorWestwood, Nigel B.en_GB
dc.contributor.authorBerger, Stuart A.en_GB
dc.contributor.authorYagita, Hideoen_GB
dc.contributor.authorOkumura, Koen_GB
dc.contributor.authorFarzaneh, Farzinen_GB
dc.contributor.authorMufti, Ghulam J.en_GB
dc.contributor.authorGuinn, Barbara-Annen_GB
dc.date.accessioned2012-05-18T10:43:42Zen
dc.date.available2012-05-18T10:43:42Zen
dc.date.issued2009-03en
dc.identifier.citationCheuk, A.T.C., Wells, J.W., Chan, L., Westwood, N.B., Berger, S.A., Yagita, H., Okumura, K., Farzaneh, F., Mufti, G.J., Guinn, B.A. (2009) 'Anti-tumor immunity in a model of acute myeloid leukemia', Leukemia and Lymphoma, 50 (3) , pp.447-54.en_GB
dc.identifier.issn1029-2403en
dc.identifier.pmid19197726en
dc.identifier.pmid19197726en
dc.identifier.doi10.1080/10428190802653776en
dc.identifier.urihttp://hdl.handle.net/10547/224557en
dc.description.abstractWhole-cell vaccines allow the induction of anti-tumor immune responses without the need to define tumor antigens. We wished to directly compare, for the first time, the capacity of B7-1, B7-2 and 4-1BB ligand (4-1BBL) costimulatory molecules to convert murine and human acute myeloid leukemia (AML) cells into whole vaccines. 32Dc-kit is a murine myeloid cell line, which develops an AML-like disease over a protracted period, emulating human AML disease development. 32Dc-kit cells were modified to express elevated levels of B7-1, B7-2 or 4-1BBL, and each led to tumor rejection, although only mice injected with 32Dc-kit/B7-2 cells were able to reject subsequent parental tumor cell challenge. T-cell deficient nude mice were able to reject the 32Dc-kit variants, but they could not reject parental cell challenge; however, we found no evidence of cytotoxic T lymphocyte or natural killer (NK) activity ex vivo suggesting that tumor cell killing was mediated by an immune response that could not be recapitulated using purified NK or T cells as lone effectors. In human allogeneic mixed lymphocyte reactions (MLRs), we found no single costimulatory molecule was more effective, suggesting that the induction of a universal anti-tumor response will require a combination of costimulatory molecules.en_GB
dc.description.sponsorshipLeukaemia and Lymphoma Research, Cancer Research U.K.en_GB
dc.language.isoenen
dc.publisherinforma healthcareen_GB
dc.relation.urlhttp://www.tandfonline.com/doi/abs/10.1080/10428190802653776?journalCode=ilal20en
dc.subjectwhole cell vaccineen_GB
dc.subjectacute myeloid leukaemiaen_GB
dc.subject4-1BB liganden_GB
dc.subjectco-stimulatory moleculesen_GB
dc.subject.mesh4-1BB Liganden
dc.subject.meshAnimalsen
dc.subject.meshAntigens, CD80en
dc.subject.meshAntigens, CD86en
dc.subject.meshCancer Vaccinesen
dc.subject.meshCell Line, Tumoren
dc.subject.meshHumansen
dc.subject.meshImmunityen
dc.subject.meshImmunotherapy, Adoptiveen
dc.subject.meshLeukemia, Myeloid, Acuteen
dc.subject.meshLymphocyte Activationen
dc.subject.meshLymphocyte Culture Test, Mixeden
dc.subject.meshMiceen
dc.titleAnti-tumor immunity in a model of acute myeloid leukemiaen
dc.typeArticleen
dc.contributor.departmentDepartment of Haematological Medicine, Allergy & Respiratory Science, MRC/Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London School of Medicine, London, UK.en_GB
dc.identifier.journalLeukemia & lymphomaen_GB
All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.